Back to Search Start Over

Distinct immune trajectories in patients with chromosome 22q11.2 deletion syndrome and immune-mediated diseases.

Authors :
Crowley, T. Blaine
Campbell, Ian M.
Liebling, Emily J.
Lambert, Michele P.
Levitt Katz, Lorraine E.
Heimall, Jennifer
Bailey, Alice
McGinn, Daniel E.
McDonald McGinn, Donna M.
Sullivan, Kathleen E.
Source :
Journal of Allergy & Clinical Immunology; Jan2022, Vol. 149 Issue 1, p445-450, 6p
Publication Year :
2022

Abstract

Identification of biomarkers associated with immune-mediated diseases in 22q11.2 deletion syndrome is an evolving field. We sought to use a carefully phenotyped cohort to study immune parameters associated with autoimmunity and atopy in 22q11.2 deletion syndrome to define biomarkers associated with immune-mediated disease in this syndrome. Chart review validated autoimmune disease and atopic condition diagnoses. Laboratory data were extracted for each subcohort and plotted according to age. A random-effects model was used to define statistical significance. CD19, CD4, and CD4/45RA lymphocyte populations were not different from the general cohort for patients with atopic conditions. CD4/45RA T cells were significantly lower in the subjects with immune thrombocytopenia compared with the general cohort, and CD4 T-cell counts were lower in patients with autoimmune thyroid disease. The mechanisms of autoimmunity in cytopenias may be distinct from those of solid-organ autoimmunity in 22q11.2 deletion syndrome. This study identifies potential biomarkers for risk stratification among commonly obtained laboratory studies. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00916749
Volume :
149
Issue :
1
Database :
Supplemental Index
Journal :
Journal of Allergy & Clinical Immunology
Publication Type :
Academic Journal
Accession number :
154266778
Full Text :
https://doi.org/10.1016/j.jaci.2021.06.007